目的 研究竹沥胶囊联合双黄连注射液治疗急慢性咽喉炎的临床疗效。方法 选取2015年1月—2016年12月在湖北医药学院附属东风医院就治的急慢性咽喉炎患者78例，随机分为对照组和治疗组，每组各39例。对照组患者静脉注射双黄连注射液，10～20 mL/次，1～2次/d。治疗组患者在对照组的基础上口服竹沥胶囊，4粒/次，3次/d。两组患者连续治疗14 d。评价治疗后两组患者临床疗效，同时比较治疗前后两组症状消失时间、血清IL-1、IL-6和TNF-α水平、咽炎症状评分以及不良反应和复发率改善情况。结果 治疗后，对照组总有效率为74.36%，显著低于治疗组的92.31%，两组比较差异具有统计学意义（P< 0.05）。治疗后，治疗组患者咽喉干痒、咽喉疼痛、黏膜充血及声音嘶哑消失时间均显著短于对照组患者，两组比较差异具有统计学意义（P< 0.05）。治疗后，治疗组患者血清IL-1、IL-6及TNF-α水平均显著下降（P< 0.05），且治疗后治疗组患者IL-1、IL-6和肿瘤坏死因子-α（TNF-α）水平明显低于对照组（P< 0.05）。治疗后，两组患者的咽炎症状积分均比治疗前有显著下降（P< 0.05）；且治疗组患者评分明显低于对照组（P< 0.05）。治疗后随访发现，治疗组患者的不良反应发生率和复发率分别为7.69%、2.56%，均显著低于对照组患者的17.95%、10.26%，两组比较差异具有统计学意义（P< 0.05）。结论 竹沥胶囊联合双黄连注射液治疗急慢性咽喉炎疗效优于单用双黄连注射液治疗，具有一定的临床推广应用价值。

Objective To study the therapeutic effect of Zhuli Capsules combined with Shuanghuanglian Injection in treatment of acute and chronic pharyngitis. Methods Patients (78 cases) with acute and chronic pharyngitis in Dongfeng Hospital Affiliated to Hubei Medical College from January 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were iv administered with Shuanghuanglian Injection, 10-20 mL/time, once to twice daily. Patients in the treatment group were po administered with Zhuli Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, clinical efficacy was evaluated, the improvement of pharyngitis symptom score, symptom disappearance time and serum IL-1, IL-6 and TNF-α levels, adverse reactions and recurrence rates in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 74.36%, which was significantly lower than 92.31% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the clinical symptom disappearance time of throat itching, sore throat, mucosal hyperemia and hoarseness in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the IL-1, IL-6, and TNF-α levels in two groups were significantly decreased (P < 0.05). And the IL-1, IL-6, and TNF-α levels in the treatment group were significantly lower than that in the control group (P < 0.05). After treatment, the pharyngitis symptom score in two groups were significantly decreased (P < 0.05). And the pharyngitis symptom score in the treatment group were significantly lower than that in the control group (P < 0.05). Follow-up after treatment, adverse reactions incidence and recurrence rate in the control group was 17.95% and 10.26%, which were significantly higher than 7.69% and 2.56% in the treatment group, respectively, and there were differences between two groups (P < 0.05). Conclusion Zhuli Capsules combined with Shuanghuanglian Injection is superior to Shuanghuanglian Injection alone in treatment of acute and chronic pharyngitis, which has a certain clinical application value.